Anifrolumab to treat a monogenic interferonopathy.

doi:10.1016/j.jaip.2024.02.013

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Anifrolumab to treat a monogenic interferonopathy.

The journal of allergy and clinical immunology. In practice - 1 May 2024

Doroudchi Mohammad-Ali, Thauland Timothy J, Patel Bhavita A, Butte Manish J

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Interferons
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed Open full text

Identifiers

PMID: 38373653
DOI: 10.1016/j.jaip.2024.02.013
PMCID: PMC12990315

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anifrolumab to treat a monogenic interferonopathy.PMID 38373653Read ↗

Genetic interferonopathies: An overviewSemantic proximity Read ↗

Type I interferonopathies—an expanding disease spectrum of immunodysregulationSemantic proximity Read ↗

The type I interferonopathies: 10 years onSemantic proximity Read ↗

Type I Interferonopathies: from a Novel Concept to Targeted Therapeutics.Semantic proximity Read ↗

[Type I interferonopathies. Literature review].Semantic proximity Read ↗

In search of a function for human type III interferons: insights from inherited and acquired deficitsSemantic proximity Read ↗

Antitumour actions of interferons: implications for cancer therapySemantic proximity Read ↗

A resourceful giant: APMV is able to interfere with the human type I interferon systemSemantic proximity Read ↗

Interferon at 50: new molecules, new potential, new (and old) questions.Semantic proximity Read ↗

Fine Tuning of a Type 1 Interferon Antagonist.Semantic proximity Read ↗

Human interferon-λ3 is a potent member of the type III interferon familySemantic proximity Read ↗

The Human Type I Interferon ReceptorSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.